AbbVie succeeds in late-stage trial for multiple myeloma drug

Summary

AbbVie announced positive results from a late-stage (Phase 3) clinical trial for its multiple myeloma drug candidate. The successful trial outcome represents a meaningful advancement toward potential regulatory approval.